"10.1371_journal.pone.0147289","plos one","2016-02-24T00:00:00Z","Mark Paul-Clark; Wagdi Elsheikh; Nicholas Kirkby; Melissa Chan; Pallavi Devchand; Terence A Agbor; Kyle L Flannigan; Charlotte Cheadle; Maxim Freydin; Angela Ianaro; Jane A Mitchell; John L Wallace","Imperial College London, London, United Kingdom; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; William Harvey Research Institute, London, United Kingdom; Mount Sinai Hospital, Icahn Medical Institute, New York, United States of America; Department of Experimental Pharmacology, Universita di Napoli Federico II, Napoli, Italy; Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta, Canada; Faculty of Medicine, Universidade Camilo Castelo Branco, São Paulo, SP, Brazil","Conceived and designed the experiments: MPC WE NK MC TAA KLF CC JAM JLW. Performed the experiments: MPC WE NK MC TAA KLF CC. Analyzed the data: MPC WE NK PD CC MF AI JAM JLW. Wrote the paper: MPC WE NK JAM JLW.","Dr. Wallace is the founder and a director of Antibe Therapeutics, which is developing ATB-346 as an anti-inflammatory drug. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.","2016","02","Mark Paul-Clark","MPC",12,TRUE,9,7,9,5,TRUE,TRUE,FALSE,0,NA,FALSE
